AU Patent

AU2017200588A1 — Treatments for gastrointestinal disorders

Assigned to Ironwood Pharmaceuticals Inc · Expires 2017-02-23 · 9y expired

What this patent protects

TREATMENTS FOR GASTROINTESTINAL DISORDERS The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, function…

USPTO Abstract

TREATMENTS FOR GASTROINTESTINAL DISORDERS The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, uncreative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017200588A1
Jurisdiction
AU
Classification
—
Expires
2017-02-23
Drug substance claim
No
Drug product claim
No
Assignee
Ironwood Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.